Results 31 to 40 of about 13,103 (221)

Narcolepsy and emotional experience: a review of the literature [PDF]

open access: yes, 2018
Narcolepsy is a chronic sleep disorder characterized by excessive daytime sleepiness, cataplexy, hypnagogic hallucinations, and sleep paralysis. This disease affects significantly the overall patient functioning, interfering with social, work, and ...
De Gennaro, Luigi   +4 more
core   +1 more source

Neural plasticity in hypocretin neurons: the basis of hypocretinergic regulation of physiological and behavioral functions in animals

open access: yesFrontiers in Systems Neuroscience, 2015
The neuronal system that resides in the perifornical and lateral hypothalamus (Pf/LH) and synthesizes the neuropeptide hypocretin/orexin participates in critical brain functions across species from fish to human.
Xiao-Bing eGao, Gretchen eHermes
doaj   +1 more source

Blast Exposure Induces Acute Alterations in Circadian Clock Genes in the Hypothalamus and Pineal Gland in Rats: An Exploratory Study

open access: yesNeurotrauma Reports, 2023
Blast-induced traumatic brain injury (bTBI) frequently results in sleep and circadian rhythm disturbances. We have investigated whether dysregulation of circadian rhythm after bTBI is mediated by dysregulation of clock genes in the hypothalamus and ...
Manoj Govindarajulu   +4 more
doaj   +1 more source

Synaptic interactions between perifornical lateral hypothalamic area, locus coeruleus nucleus and the oral pontine reticular nucleus are implicated in the stage succession during sleep-wakefulness cycle [PDF]

open access: yes, 2013
This Document is Protected by copyright and was first published by Frontiers. All rights reserved. it is reproduced with permissionThe perifornical area in the posterior lateral hypothalamus (PeFLH) has been implicated in several physiological functions ...
Garzón, Miguel   +3 more
core   +3 more sources

The hypocretin/orexin antagonist almorexant promotes sleep without impairment of performance in rats. [PDF]

open access: yes, 2014
The hypocretin receptor (HcrtR) antagonist almorexant (ALM) has potent hypnotic actions but little is known about neurocognitive performance in the presence of ALM.
Kilduff, Thomas S   +4 more
core   +2 more sources

Human hypocretin-deficient narcolepsy - aberrant food choice due to impaired taste? [PDF]

open access: yesSleep Science
Authors demonstrate that patients with narcolepsy type 1 (N1) have more tendency of eat salty snacks after satiety than health volunteers. A few mechanisms to explain the weight gain have been discussed in narcolepsy.
Giselle de Martin Truzzi   +2 more
doaj   +1 more source

The Roles of Dopamine and Hypocretin in Reward: A Electroencephalographic Study. [PDF]

open access: yesPLoS ONE, 2015
The proper functioning of the mesolimbic reward system is largely dependent on the neurotransmitter dopamine. Recent evidence suggests that the hypocretin system has significant projections to this reward system.
Armand Mensen   +5 more
doaj   +1 more source

DEC2 modulates orexin expression and regulates sleep. [PDF]

open access: yes, 2018
Adequate sleep is essential for physical and mental health. We previously identified a missense mutation in the human DEC2 gene (BHLHE41) leading to the familial natural short sleep behavioral trait.
Fu, Ying-Hui   +7 more
core   +1 more source

The hypocretins and sleep [PDF]

open access: yesThe FEBS Journal, 2005
The hypocretins (also called the orexins) are two neuropeptides derived from the same precursor whose expression is restricted to a few thousand neurons of the lateral hypothalamus. Two G‐protein coupled receptors for the hypocretins have been identified, and these show different distributions within the central nervous system and differential ...
Luis, de Lecea, J Gregor, Sutcliffe
openaire   +2 more sources

Phase II Proof-of-Concept Trial of the Orexin Receptor Antagonist Filorexant (MK-6096) in Patients with Major Depressive Disorder. [PDF]

open access: yes, 2017
BackgroundWe evaluated the orexin receptor antagonist filorexant (MK-6096) for treatment augmentation in patients with major depressive disorder.MethodsWe conducted a 6-week, double-blind, placebo-controlled, parallel-group, Phase II, proof-of-concept ...
Ceesay, Paulette   +9 more
core   +1 more source

Home - About - Disclaimer - Privacy